Skip to main content
. 2020 Apr 4;12(4):878. doi: 10.3390/cancers12040878

Figure 1.

Figure 1

Differential cytotoxicity and synergy of rucaparib and PF-477736 in BRCA2 mutant and corrected cells. V-C8 and V-C8.B2 cells were exposed to drugs at the indicated concentration for 24 h prior to replacement with drug-free medium for 7–10 days to allow colony formation. (a) Rucaparib, (b) PF-477736, (c) the combination of rucaparib with 50 nM PF-477736 in V-C8 B2 cells, and (d) the combination of rucaparib with 50 nM PF-477736 in V-C8 cells. Data are the mean and standard error of three independent experiments.